hrp0098p3-10 | Adrenals and HPA Axis | ESPE2024

Letrozole as Treatment for Severely Advanced Bone Age in Children with Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency

Wang Qian , Li Guimei

Objective: To investigate the feasibility and rationality of letrozole (Lz) as treatment for severely advanced bone age (BA) in children with 21-Hydroxylase Deficiency (21-OHD).Methods: This was a retrospective self-control study to test the possibility of Lz that a decrease in the rate of bone maturation and an increase in predicted adult height (PAH).Results: The improvement of h...

hrp0098p3-275 | Late Breaking | ESPE2024

Effects of gonadotropin-releasing hormone analogue (GnRHa) combined with recombinant growth hormone (rhGH) on growth of girls with central precocious puberty or early and fast puberty

Qiao Yu , Li Guimei

Background: Girls diagnosed with central precocious puberty (CPP) or early and fast puberty (EFP) tend to exhibit temporarily rapid acceleration in growth due to increased sex hormone production or exposure, leading to premature closure of the growth plate and a shorter final adult height (FAH). Rapid progression of the secondary sexual characteristics in children can also cause poor social adaptability, psychological stress, and emotional disorders. CPP/EFP c...

hrp0098rfc14.3 | Fetal and Neonatal Endocrinology | ESPE2024

Complex Glycerol Kinase Deficiency: four new cases and a review of the literature

Wang Fengxue , Shang Xiaohong , Li Guimei

Objective: Complex glycerol kinase deficiency (CGKD) is a rare genetic syndrome which belongs to the group of contiguous gene syndromes and is caused by microdeletion of genes located in Xp21, which also be called Xp21 contiguous gene deletion syndrome. Patients with CGKD present with features characteristic for adrenal hypoplasia congenita (AHC), glycerol kinase deficiency (GKD), Duchenne muscular dystrophy (DMD) and sometimes intellectual disability or hyper...

hrp0098p1-81 | Pituitary, Neuroendocrinology and Puberty 1 | ESPE2024

Changes of lipid and glucose metabolism indices in patients with transition growth hormone deficiency after rhGH replacement therapy

Wang Fengxue , Li Guimei , Shang Xiaohong

Background: Objective to determine the efficacy of short-term rhGH treatment on metabolic indices in TGHD patients by comparing the changes in blood glucose and lipid levels before and after rhGH replacement therapy.Methods: The levels of metabolic indices (AST, ALT, TC, TG, HDL-C, LDL-C, FBG, GA, and URIC) in their basic state in TGHD patients were recorded, and differences in these levels between the TGHD and control g...

hrp0098p2-164 | Growth and Syndromes | ESPE2024

Clinical and genetic analysis of ulnar-mammary syndrome caused by a novel TBX3 mutation in a Chinese boy and literature review

Yang Jianmei , Sun Yan , Li Guimei

Ulnar-mammary syndrome (UMS) is caused by TBX3 mutation and is a disorder characterized by altered limb, breast, tooth, hair, apocrine gland, and genital development. The detailed genotype-phenotype correlation of TBX3 -related diseases was analysed by the 5.5th UMS case analysis, and all reported cases of UMS were summarized and discussed.Methods: The clinical and genetic data of a boy with UMS were carefully analysed....

hrp0082p2-d2-603 | Thyroid (1) | ESPE2014

Euthyroid Sick Syndrome in Children with Diabetic Ketoacidosis

Hu Yanyan , Li Guimei , Wang Qian , Wang Zengmin , Wang Fengxue

Background: The correlation between free thyroid hormones and poor diabetic control in children with diabetic ketoacidosis (DKA) and the effects of thyroid hormone therapy on euthyroid sick syndrome (ESS) remain unclear.Objective and hypotheses: To investigate characteristics of ESS in children with DKA and the effects of thyroid hormone therapy on ESS. In children with DKA, free thyroid hormones may be associated with the severity of DKA and thyroid hor...

hrp0098p1-80 | Pituitary, Neuroendocrinology and Puberty 1 | ESPE2024

A 12-month, Open-Label, Single-Arm, Phase 3 Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty

Yu Xiao , Cheng Xinran , Xu Xu , Gong Chunxiu , Li Guimei , Yao Hui , Zhou Li , Zhong Yan , Yang Yu , Luo Feihong , Zhang Yining , Huang Frank , Shi Xiaofeng , Cabri Patrick , Luo Xiaoping

Objectives: The gonadotropin-releasing hormone (GnRH) analogue triptorelin is used to treat central precocious puberty (CPP) in 1-, 3- and 6-month prolonged-release (PR) formulations. Currently, only the 1- and 3-month formulations are approved for CPP in China. However, the 6-month formulation is available for CPP treatment in numerous countries; this study assessed the efficacy and safety of this formulation in Chinese children with CPP.<p class="abstext...